This study investigates the safety and effectiveness of an investigational medication for people aged 12 and older with moderate to severe atopic dermatitis. Participants will be involved in the study for up to 284 weeks. This includes a screening period lasting 2 to 4 weeks, a treatment period of up …
This study investigates the efficacy and safety of an investigational medication for subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis (AD). The study involves participants who have not responded adequately to previous biologic or oral JAK inhibitor therapies, and who are currently using topical corticosteroids …
This study investigates the effect of an investigational medication, an Anti-OX40L Monoclonal Antibody, in adults with moderate to severe atopic dermatitis. The study will compare the investigational medication to other treatment arms to assess its effectiveness.Participants will be randomly assigned to one of five study arms in a double-blind manner, …
This study investigates the treatment of atopic dermatitis (AD) in adolescents and adults who start or switch systemic treatments. This study aims to understand the unmet needs of patients with AD and evaluate the safety and effectiveness of systemic treatments in real-world settings.Participants will be observed as they receive their …
This study investigates the effects of atopic dermatitis (AD) on pregnancy outcomes. This observational study will compare the incidence of adverse pregnancy outcomes, such as miscarriage or stillbirth, and the prevalence of adverse infant outcomes, like major congenital malformations or being small for gestational age, in women with AD who …
This study investigates pregnancy and infant outcomes in women exposed to an investigational medication during pregnancy. The study compares these outcomes with those of two other groups: pregnant women with similar health conditions who are not exposed to the investigational medication, and healthy pregnant women. The primary focus is on …
